Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from multiple nucleos(t)ide analogues to tenofovir alafenamide monotherapy in chronic hepatitis B
jRCT1031220145Not yet recruiting
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB). Primary endpoints: Viral response rate at 4 weeks, Viral response rate at 8 weeks and 3 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT1031220145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220145.